The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.

Proc (Bayl Univ Med Cent)Jun 30, 2026 (epub)
Clinical ResearchPulmonologyRheumatologyOpen access

Nattanicha Chaisrimaneepan, Pitchaporn Yingchoncharoen, Tulaton Sodsri et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the risk of lung cancer in patients with ANCA-associated vasculitis (AAV). Analyzing 13 studies with 8004 participants, the pooled relative risk for lung cancer was found to be 2.08 (95% CI, 1.52-2.83), indicating a significant increase in risk compared to the general population.

Key findings

  • The pooled relative risk for lung cancer in AAV patients was 2.08 (95% CI, 1.52-2.83).
  • The analysis included 13 studies with a total of 8004 participants.
  • Follow-up duration across studies ranged from 2 to 26 years.
  • Moderate heterogeneity was observed with I² = 48.38%.

Why it matters

Understanding the increased risk of lung cancer in patients with AAV is crucial for clinicians, as it may influence surveillance and management strategies for this population.

Source

PubMed · PMID 42376993Free full text on PubMed Central

Published in Proc (Bayl Univ Med Cent). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.